Dr. Stephan C. Sharp, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TN license 019021 · TN license 19021
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 13 companies. The companies reported $2,349,639 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A phase 12 randomized doubleblinded study to evaluate the safety tolerability and immunogenicity of modified rna vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity
Hoffmann-la Roche Limited - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity
Genentech, Inc. - CT-388-104 OW/OB with T2D
Genentech, Inc. - A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly and Company · Active, not recruiting · NCT06037252 - A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Novavax Inc - The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
Seqirus USA Inc · Completed · NCT06015282
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.